Top

Published in:

Open Access 01-04-2019 | Insulins | Original Article

1,25-Dihydroxy vitamin D3 treatment attenuates osteopenia, and improves bone muscle quality in Goto-Kakizaki type 2 diabetes model rats

Authors: Yanlong Liang, Yanzhi Liu, Wenxiu Lai, Minqun Du, Shuhui Li, Limin Zhou, Yulin Mo, Pan Wang, Yalin Min, Liao Cui

Published in: Endocrine | Issue 1/2019

Abstract

Purpose:

Osteopenia and skeletal fragility are considered to be the complications associated with type 2 diabetes mellitus (T2DM). The relationship between glucose metabolism, skeletal quality, and vitamin D have not been completely understood. We aimed to demonstrate a comprehensive bone quality profile in a T2DM model subject and to investigate whether 1, 25-dihydroxy vitamin D3 could prevent osteopenia and skeletal fragility in the diabetes model rats.

Methods:

Daily calcitriol (a 1, 25-dihydroxy vitamin D3 formulation, 0.045 μg/kg/day) treatment was administered to 21-week-old male Goto-Kakizaki (GK) rats (a genetic non-obese and non-insulin-dependent spontaneous diabetes rat model) for 20 weeks and the results were compared with those in untreated GK rats, and wild-type animals.

Results:

Micro-computed tomography, histomorphometry, and bone mineral density analysis demonstrated that T2DM induced significant osteopenia, and impairment of bone microarchitecture and biomechanical properties in GK rats. T2DM also significantly decreased bone formation and increased bone resorption parameters in three regions of the skeleton (proximal tibia, mid-shaft of the tibia, and lumbar vertebrae), and increased carboxy-terminal type I collagen crosslinks, tartrate-resistant acid phosphatase, muscle ubiquitin C, and bone thioredoxin interacting protein (TXNIP) expression. Calcitriol treatment significantly alleviated bone loss, and improved bone microarchitecture and biomechanical properties and also decreased serum glucose and glycated serum protein levels. Biomarkers of bone formation were significantly increased, while muscle ubiquitin C and bone TXNIP expression were significantly decreased following calcitriol treatment.

Conclusions:

These results suggest that 1,25-dihydroxy vitamin D3 treatment effectively attenuates osteopenia, and improves bone and muscle quality in GK type 2 diabetes model rats.

Roglic, G., World Health Organization: Global Report On Diabetes. (World Health Organization, Geneva, Switzerland 2016)

E.W. Gregg, Y. Li, J. Wang, N.R. Burrows, M.K. Ali, D. Rolka, D.E. Williams, L. Geiss, Changes in diabetes-related complications in the United States, 1990-2010. N. Engl. J. Med. 370(16), 1514–1523 (2014). https://doi.org/10.1056/NEJMoa1310799 CrossRefPubMed

M. Leenders, L.B. Verdijk, L. van der Hoeven, J.J. Adam, J. van Kranenburg, R. Nilwik, L.J. van Loon, Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J. Am. Med. Dir. Assoc. 14(8), 585–592 (2013). https://doi.org/10.1016/j.jamda.2013.02.006 CrossRefPubMed

S.W. Park, B.H. Goodpaster, J.S. Lee, L.H. Kuller, R. Boudreau, N. de Rekeneire, T.B. Harris, S. Kritchevsky, F.A. Tylavsky, M. Nevitt, Y.W. Cho, A.B. Newman, A. Health, S. Body Composition, Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 32(11), 1993–1997 (2009). https://doi.org/10.2337/dc09-0264 CrossRefPubMedPubMedCentral

J. Mitri, M.D. Muraru, A.G. Pittas, Vitamin D and type 2 diabetes: a systematic review. Eur. J. Clin. Nutr. 65(9), 1005–1015 (2011). https://doi.org/10.1038/ejcn.2011.118 CrossRefPubMedPubMedCentral

S. Afzal, S.E. Bojesen, B.G. Nordestgaard, Low 25-hydroxyvitamin D and risk of type 2 diabetes: a prospective cohort study and metaanalysis. Clin. Chem. 59(2), 381–391 (2013). https://doi.org/10.1373/clinchem.2012.193003 CrossRefPubMed

Y. Song, L. Wang, A.G. Pittas, L.C. Del Gobbo, C. Zhang, J.E. Manson, F.B. Hu, Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care 36(5), 1422–1428 (2013). https://doi.org/10.2337/dc12-0962 CrossRefPubMedPubMedCentral

P.C. Guest, Characterization of the Goto-Kakizaki (GK) Rat Model of Type 2 Diabetes. Methods Mol. Biol. 1916, 203–211 (2019). https://doi.org/10.1007/978-1-4939-8994-2_19 CrossRefPubMed

D.W. Dempster, J.E. Compston, M.K. Drezner, F.H. Glorieux, J.A. Kanis, H. Malluche, P.J. Meunier, S.M. Ott, R.R. Recker, A.M. Parfitt, Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Mineral. Res.: Off. J. Am. Soc. Bone Mineral. Res. 28(1), 2–17 (2013). https://doi.org/10.1002/jbmr.1805 CrossRef

10.

Y. Liu, Y. Cui, Y. Chen, X. Gao, Y. Su, L. Cui, Effects of dexamethasone, celecoxib, and methotrexate on the histology and metabolism of bone tissue in healthy Sprague Dawley rats. Clin. Interv. Aging 10, 1245–1253 (2015). https://doi.org/10.2147/CIA.S85225 CrossRefPubMedPubMedCentral

11.

Y. Liu, Y. Cui, X. Zhang, X. Gao, Y. Su, B. Xu, T. Wu, W. Chen, L. Cui, Effects of salvianolate on bone metabolism in glucocorticoid-treated lupus-prone B6.MRL-Fas (lpr) /J mice. Drug Des. Devel Ther. 10, 2535–2546 (2016). https://doi.org/10.2147/DDDT.S110125 CrossRefPubMedPubMedCentral

12.

T. Ahmad, C. Ohlsson, M. Saaf, C.G. Ostenson, A. Kreicbergs, Skeletal changes in type-2 diabetic Goto-Kakizaki rats. J. Endocrinol. 178(1), 111–116 (2003)CrossRefPubMed

13.

L. Zhang, Y. Liu, D. Wang, X. Zhao, Z. Qiu, H. Ji, H. Rong, Bone biomechanical and histomorphometrical investment in type 2 diabetic Goto-Kakizaki rats. Acta Diabetol. 46(2), 119–126 (2009). https://doi.org/10.1007/s00592-008-0068-1 CrossRefPubMed

14.

S. Battault, S.J. Whiting, S.L. Peltier, S. Sadrin, G. Gerber, J.M. Maixent, Vitamin D metabolism, functions and needs: from science to health claims. Eur. J. Nutr. 52(2), 429–441 (2013). https://doi.org/10.1007/s00394-012-0430-5 CrossRefPubMed

15.

M.C. Chapuy, M.E. Arlot, F. Duboeuf, J. Brun, B. Crouzet, S. Arnaud, P.D. Delmas, P.J. Meunier, Vitamin D3 and calcium to prevent hip fractures in elderly women. N. Engl. J. Med. 327(23), 1637–1642 (1992). https://doi.org/10.1056/NEJM199212033272305 CrossRefPubMed

16.

A.M. Grant, A. Avenell, M.K. Campbell, A.M. McDonald, G.S. MacLennan, G.C. McPherson, F.H. Anderson, C. Cooper, R.M. Francis, C. Donaldson, W.J. Gillespie, C.M. Robinson, D.J. Torgerson, W.A. Wallace, R.T. Group, Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365(9471), 1621–1628 (2005). https://doi.org/10.1016/S0140-6736(05)63013-9 CrossRefPubMed

17.

A.G. Pittas, J. Lau, F.B. Hu, B. Dawson-Hughes, The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 92(6), 2017–2029 (2007). https://doi.org/10.1210/jc.2007-0298 CrossRefPubMedPubMedCentral

18.

M. Kuroda, H. Sakaue, [Role of vitamin D and calcium in obesity and type 2 diabetes]. Clin. Calcium 26(3), 349–354 (2016). CliCa1603349354.PubMed

19.

D. Shehab, K. Al-Jarallah, O.A. Mojiminiyi, H. Al Mohamedy, N.A. Abdella, Does Vitamin D deficiency play a role in peripheral neuropathy in Type 2 diabetes? Diabet. Med. 29(1), 43–49 (2012). https://doi.org/10.1111/j.1464-5491.2011.03510.x CrossRefPubMed

20.

S.,St Nazarian, J.V. Peter, R.C. Boston, S.A. Jones, C.N. Mariash, Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose. Transl. Res. 158(5), 276–281 (2011). https://doi.org/10.1016/j.trsl.2011.05.002 CrossRefPubMedPubMedCentral

21.

J.A. Alvarez, A. Ashraf, Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis. Int. J. Endocrinol. 2010, 351385 (2010). https://doi.org/10.1155/2010/351385 CrossRefPubMed

22.

Z. Asemi, T. Hashemi, M. Karamali, M. Samimi, A. Esmaillzadeh, Effects of vitamin D supplementation on glucose metabolism, lipid concentrations, inflammation, and oxidative stress in gestational diabetes: a double-blind randomized controlled clinical trial. Am. J. Clin. Nutr. 98(6), 1425–1432 (2013). https://doi.org/10.3945/ajcn.113.072785 CrossRefPubMed

23.

A. Talaei, M. Mohamadi, Z. Adgi, The effect of vitamin D on insulin resistance in patients with type 2 diabetes. Diabetol. Metab. Syndr. 5(1), 8 (2013). https://doi.org/10.1186/1758-5996-5-8 CrossRefPubMedPubMedCentral

24.

F. Strobel, J. Reusch, M. Penna-Martinez, E. Ramos-Lopez, E. Klahold, C. Klepzig, J. Wehrle, H. Kahles, K. Badenhoop, Effect of a randomised controlled vitamin D trial on insulin resistance and glucose metabolism in patients with type 2 diabetes mellitus. Horm. Metab. Res. 46(1), 54–58 (2014). https://doi.org/10.1055/s-0033-1358453 CrossRefPubMed

25.

A.M. Borissova, T. Tankova, G. Kirilov, L. Dakovska, R. Kovacheva, The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int. J. Clin. Pract. 57(4), 258–261 (2003)PubMed

26.

J.C. Seida, J. Mitri, I.N. Colmers, S.R. Majumdar, M.B. Davidson, A.L. Edwards, D.A. Hanley, A.G. Pittas, L. Tjosvold, J.A. Johnson, Clinical review: Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 99(10), 3551–3560 (2014). https://doi.org/10.1210/jc.2014-2136 CrossRefPubMedPubMedCentral

27.

S.W. Muir, M. Montero-Odasso, Effect of vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis. J. Am. Geriatr. Soc. 59(12), 2291–2300 (2011). https://doi.org/10.1111/j.1532-5415.2011.03733.x CrossRefPubMed

28.

R.W. Jackman, S.C. Kandarian, The molecular basis of skeletal muscle atrophy. Am. J. Physiol. Cell. Physiol. 287(4), C834–C843 (2004). https://doi.org/10.1152/ajpcell.00579.2003 CrossRefPubMed

29.

W.E. Mitch, A.L. Goldberg, Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335(25), 1897–1905 (1996). https://doi.org/10.1056/NEJM199612193352507 CrossRefPubMed

30.

S.C. Manolagas, From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 31(3), 266–300 (2010). https://doi.org/10.1210/er.2009-0024 CrossRefPubMedPubMedCentral

31.

D.A. Callaway, J.X. Jiang, Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. J. Bone Miner. Metab. 33(4), 359–370 (2015). https://doi.org/10.1007/s00774-015-0656-4 CrossRefPubMed

32.

S. Tangvarasittichai, Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J. Diabetes 6(3), 456–480 (2015). https://doi.org/10.4239/wjd.v6.i3.456 CrossRefPubMedPubMedCentral

33.

T. Lekva, T. Ueland, H. Boyum, J.A. Evang, K. Godang, J. Bollerslev, TXNIP is highly regulated in bone biopsies from patients with endogenous Cushing’s syndrome and related to bone turnover. Eur. J. Endocrinol. 166(6), 1039–1048 (2012). https://doi.org/10.1530/EJE-11-1082 CrossRefPubMed

Title: 1,25-Dihydroxy vitamin D3 treatment attenuates osteopenia, and improves bone muscle quality in Goto-Kakizaki type 2 diabetes model rats
Authors: Yanlong Liang
Yanzhi Liu
Wenxiu Lai
Minqun Du
Shuhui Li
Limin Zhou
Yulin Mo
Pan Wang
Yalin Min
Liao Cui
Publication date: 01-04-2019
Publisher: Springer US
Keywords: Insulins
Insulins
Type 2 Diabetes
Published in: Endocrine / Issue 1/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-01857-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose:

Methods:

Results:

Conclusions:

Please log in to get access to this content

Other articles of this Issue 1/2019

Comparison among TIRADS (ACR TI-RADS and KWAK- TI-RADS) and 2015 ATA Guidelines in the diagnostic efficiency of thyroid nodules

Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis

Acromegaly can be cured by first-line pasireotide treatment?

Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?

Preliminary report of microwave ablation for the primary papillary thyroid microcarcinoma: a large-cohort of 185 patients feasibility study

A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials